Worldwide Pharmaceutical Contract Research Services Industry Report to 2030

News provided by

Sep 28, 2021, 17:30 ET

DUBLIN, Sept. 28, 2021 /PRNewswire/ -- The "Pharmaceutical Contract Research Services Market by Scale of Operation, Target Therapeutic Areas and Key Geographies and Rest of the World): Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on contract service providers engaged in discovery, preclinical and clinical research of small molecule drugs. The study features in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA's Center for Drug Evaluation and Research approved 35 small molecule drugs, representing 66% of the total number of new molecular entities (NMEs) clearing regulatory review in the same year. It is worth highlighting that the process of drug development, beginning from the discovery of a pharmacological lead to the commercialization of a clinically validated product, takes around 10-15 years. Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion. Further, it is a well-known fact that only a small proportion of lead molecules that are shortlisted for further investigation during the discovery phase, actually make it into the clinical phase, and an even lesser number of product candidates enter the market. Therefore, to optimize on internal resource utilization and save costs, innovator companies in the pharmaceutical industry are increasingly outsourcing various aspects of their discovery-stage operations to specialty contract research organizations (CROs).

Modern CROs offer a plethora of pharmaceutical discovery (such as target discovery & validation, hit identification (using strategies such as high-throughput screening, fragment-based screening, virtual screening, knowledge-based screening and DNA-encoded libraries), and lead generation / optimization) and product development related services, leveraging a variety of advanced technologies to cater to the evolving needs of sponsors / clients. As indicated earlier, engaging third party service providers offers both time and cost related benefits to drug / therapy developers. Currently, over 500 companies / organization claim to be actively providing contract research services for small molecule drugs. In the recent past, many of the service providers in this domain forged strategic alliances and / or acquired other players, in order to further enhance their respective service portfolios and thereby, consolidate their presence in the industry. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model. Based on prevalent trends and projections of how the pharmaceutical pipeline is likely to evolve over the coming years, we believe that demand for pharmaceutical CROs is going to grow at a steady pace. Consequently, the small molecule drug discovery and development services market is anticipated to witness consistent growth till 2030.

Key Questions Answered

Who are the leading players offering contract research services for small molecules?
Which partnership models are commonly adopted by stakeholders engaged in this industry?
What are the key value drivers of the merger and acquisition activity observed within this domain?
What are the likely future trends in contract research services market?
How is the current and future opportunity likely to be distributed across key market segments?
What is the total cost of ownership required to set up a pharmaceutical contract research organization?

Amongst other elements, the report includes:

A detailed review of the overall landscape of the pharmaceutical services market, highlighting the contributions of CROs, along with information on their year of establishment, company size, scale of operation (discovery, preclinical and clinical), location of headquarters, type(s) of services offered (target discovery & validation, hit identification, hit-to-lead & lead generation, lead optimization, bioanalytical studies, other preclinical services, clinical trials related services, consulting and regulatory affairs management), hit identification strategy used (high-throughput screening, fragment based screening, virtual screening (structure based virtual screening, ligand based virtual screening and unspecified virtual screening), knowledge based screening, DNA Encoded Library (DEL) based screening and others), type of business model (fee-for-service and full time equivalent) and target therapeutic area.
Elaborate profiles of prominent CROs engaged in offering pharmaceutical related services. Each company profile features a brief overview of the company, its financial information (if available), service portfolio and recent developments and an informed future outlook.
An insightful competitiveness analysis, highlighting prominent pharmaceutical contract service providers based on supplier strength (considering a company's years of experience), and service strength (which takes into account the service offerings, scale of operation, hit identification strategies and subject specific agreements).
An analysis of the recent collaborations (signed since 2018) focused on the CROs offering pharmaceutical related services, based on various parameters, such as year of agreement, type of agreement, scale of operation and target therapeutic area.
A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2018-2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year, type of acquisition and geographical location of the companies.
A region-wise, detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider. It features an informed estimate of direct and indirect expenses taking into consideration close to 100 relevant parameters over a span of 20 years.
A case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Discovery and Validation
3.3.3. Hit Generation
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Libraries Screening
3.3.4. Hit-to-Lead and Lead Generation
3.3.5. Lead Optimization
3.4. Challenges Associated with Small Molecule Discovery
3.5. Need for Outsourcing Drug Discovery Operations
3.6 Guidelines for Selecting a Contract Research Service Provider
3.7. Concluding Remarks

4. PHARMACEUTICAL CONTRACT RESEARCH SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical Contract Research Service Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Company Size and Scale of Operation
4.2.6. Analysis by Types of Services Offered
4.2.7. Analysis by Location of Headquarters and Types of Services Offered
4.2.8. Analysis by Hit Identification Strategy Used
4.2.9. Analysis by Type of Business Model
4.2.10. Analysis by Target Therapeutic Area

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Pharmaceutical Contract Research Service Providers in North America
5.2.1. Albany Molecular Research (AMRI)
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Service Portfolio
5.2.1.4. Recent Developments and Future Outlook
5.2.2. BioDuro
5.2.2.1. Company Overview
5.2.2.2. Service Portfolio
5.2.2.3. Recent Developments and Future Outlook
5.2.3. BOC Sciences
5.2.3.1. Company Overview
5.2.3.2. Service Portfolio
5.2.3.3. Recent Developments and Future Outlook
5.2.4. Catalent Pharma
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Service Portfolio
5.2.4.4. Recent Developments and Future Outlook
5.2.5. Charles River Laboratories
5.2.5.1. Company Overview
5.2.5.2. Financial Information
5.2.5.3. Service Portfolio
5.2.5.4. Recent Developments and Future Outlook
5.2.6. ChemDiv
5.2.6.1. Company Overview
5.2.6.2. Service Portfolio
5.2.6.3. Recent Developments and Future Outlook
5.2.7. Covance
5.2.7.1. Company Overview
5.2.7.2. Financial Information
5.2.7.3. Service Portfolio
5.2.7.4. Recent Developments and Future Outlook
5.2.8. Medpace
5.2.8.1. Company Overview
5.2.8.2. Financial Information
5.2.8.3. Service Portfolio
5.2.8.4. Recent Developments and Future Outlook
5.2.9. QPS
5.2.9.1. Company Overview
5.2.9.2. Service Portfolio
5.2.9.3. Recent Developments and Future Outlook
5.3. Pharmaceutical Contract Research Service Providers in Europe
5.3.1. Concept Life Sciences
5.3.1.1. Company Overview
5.3.1.2. Service Portfolio
5.3.1.3. Recent Developments and Future Outlook
5.3.2. Evotec
5.3.2.1. Company Overview
5.3.2.2. Financial Information
5.3.2.3. Service Portfolio
5.3.2.4. Recent Developments and Future Outlook
5.4. Pharmaceutical Contract Research Service Providers in Asia-Pacific
5.4.1. ChemPartner
5.4.1.1. Company Overview
5.4.1.2. Financial Information
5.4.1.3. Service Portfolio
5.4.1.4. Recent Developments and Future Outlook
5.4.2. Pharmaron
5.4.2.1. Company Overview
5.4.2.2. Service Portfolio
5.4.2.3. Recent Developments and Future Outlook
5.4.3. Syngene
5.4.3.1. Company Overview
5.4.3.2. Financial Information
5.4.3.3. Service Portfolio
5.4.3.4. Recent Developments and Future Outlook
5.4.4. Torrent Pharma
5.4.4.1. Company Overview
5.4.4.2. Financial Information
5.4.4.3. Service Portfolio
5.4.4.4. Recent Developments and Future Outlook
5.4.5. WuXi AppTec
5.4.5.1. Company Overview
5.4.5.2. Financial Information
5.4.5.3. Service Portfolio
5.4.5.4. Recent Developments and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Company Competitiveness Analysis: Pharmaceutical Contract Research Service Providers
6.4.1. Pharmaceutical Contract Research Service Providers based in North America
6.4.2. Pharmaceutical Contract Research Service Providers based in Europe
6.4.3. Pharmaceutical Contract Research Service Providers based in Asia- Pacific and Rest of the World

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Pharmaceutical Contract Research Service Providers: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Target Therapeutic Area
7.3.5. Analysis by Year of Partnership and Type of Partner
7.3.6. Analysis by Type of Partnership and Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Regional Analysis
7.3.8.1. Intercontinental and Intracontinental Agreements

8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Pharmaceutical Contract Research Service Providers: Mergers and Acquisitions
8.3.1. Analysis by Year of Acquisition
8.3.2. Analysis by Geography
8.3.3. Intercontinental and Intracontinental Deals
8.4. Analysis by Key Value Drivers
8.4.1. Mergers and Acquisitions: Analysis by Key Value Drivers
8.5. Valuation Analysis: Acquisition Deal Multiples
8.5.1. Prominent Acquirers: Analysis by Number of Acquisitions

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10. TOTAL COST OF OWNERSHIP IN PHARMACEUTICAL CONTRACT RESEARCH ORGANIZATION
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Output

11. CASE STUDY: BIOPHARMACEUTICAL CONTRACT RESEARCH SERVICES MARKET

12. EXECUTIVE INSIGHTS

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

For more information about this report visit https://www.researchandmarkets.com/r/d6o4yx

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets